CV-8102 is a mRNA Vaccine owned by Curevac, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.
CV-8102 acts by agonizing TLR7/TLR8 and RIG-I receptors. Expression of TLRs on tumor cells, which is known to mediate innate immune response, influences the proliferation and migration of tumor cells. Activation of different TLRs in cancer cells may play opposite role, antitumor or protumor. The drug candidate by agonising TLR7/TLR8 receptors checks the tumor progression. RIG-I receptor activation results in up regulation, mitochondrial localization of RIG-I and activation of proinflammatory transcription factors STAT1 and NF-κB. RIG-I agonist triggers the extrinsic apoptosis pathway and pyroptosis, a highly immunogenic form of cell death.
The revenue for CV-8102 is expected to reach a total of $3.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the CV-8102 NPV Report.
CV-8102 is originated and owned by Curevac.
CV-8102 is under development for the prevention of advanced melanoma, cutaneous squamous cell carcinoma of skin, head and neck squamous cell carcinoma, adenoid cystic carcinoma and superficially injectable tumor lesions. The therapeutic candidate is administered through intramuscular, intradermal and intratumoral routes. It acts by targeting TLR7/TLR8 and RIG-I receptors. It is developed based on RNAdjuvant technology. It was under development of rabies virus infection.
Curevac is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger rna molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna and Cvsqiv. Curevac mrna-based prophylactic vaccines candidates comprise cv7202 and cv8102. it also carries out the research and development. The company Cv8102, a lead oncology candidate is designed to modulate the tumor microenvironment. Its products are used in the treatment of prostate cancer and non-small cell lung cancer, and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. Curevac is headquartered in Tubingen, Baden-Wurttemberg, Germany.
The company reported revenues of (Euro) EUR103 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR48.9 million in FY2020. The operating loss of the company was EUR412.3 million in FY2021, compared to an operating loss of EUR109.8 million in FY2020. The net loss of the company was EUR411.7 million in FY2021, compared to a net loss of EUR129.1 million in FY2020. The company reported revenues of EUR11.2 million for the third quarter ended September 2022, a decrease of 44.3% over the previous quarter.
Quick View – CV-8102
|Highest Development Stage|